We report a case in which selegiline, an irreversible monoamine oxidase B (MAO-B) inhibitor, greatly improved depressive symptoms in an adult with stage 5 treatment-resistant major depressive disorder. Four antidepressants and four augmentation therapies had previously been ineffective or intolerable, and electroconvulsive therapy had only a temporary effect. After 20 weeks of treatment with selegiline (10 mg/day), the patient's score on the 17-item Hamilton Depression Rating Scale (HDRS) had decreased from 19 to 4 points. [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET) showed increased glucose metabolism in the bilateral basal ganglia after initiating selegiline treatment; blood dopamine levels were also increased after selegiline treatment. These results raise the possibility that selegiline enhances dopaminergic neural transmission in treatment-resistant depression, thus leading to an improvement in depressive symptoms. © 2013 Kitaichi et al.
CITATION STYLE
Kitaichi, Y., Inoue, T., Mitsui, N., Nakagawa, S., Kameyama, R., Hayashishita, Y., … Koyama, T. (2013). Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: A case report. Neuropsychiatric Disease and Treatment, 9, 1591–1594. https://doi.org/10.2147/NDT.S49261
Mendeley helps you to discover research relevant for your work.